WO2000077241A2 - Heparanase assay - Google Patents
Heparanase assay Download PDFInfo
- Publication number
- WO2000077241A2 WO2000077241A2 PCT/GB2000/002117 GB0002117W WO0077241A2 WO 2000077241 A2 WO2000077241 A2 WO 2000077241A2 GB 0002117 W GB0002117 W GB 0002117W WO 0077241 A2 WO0077241 A2 WO 0077241A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- solid phase
- phase support
- moiety
- hsgag
- binding
- Prior art date
Links
- 108010037536 heparanase Proteins 0.000 title claims abstract description 58
- 102100024025 Heparanase Human genes 0.000 title claims abstract description 54
- 238000003556 assay Methods 0.000 title claims description 29
- 239000007790 solid phase Substances 0.000 claims abstract description 72
- 239000000758 substrate Substances 0.000 claims abstract description 38
- 230000027455 binding Effects 0.000 claims abstract description 37
- 238000000034 method Methods 0.000 claims abstract description 33
- 230000000694 effects Effects 0.000 claims abstract description 30
- 229920000307 polymer substrate Polymers 0.000 claims abstract description 22
- 210000001216 paracrine cell Anatomy 0.000 claims abstract description 21
- 108091005804 Peptidases Proteins 0.000 claims abstract description 8
- 102000035195 Peptidases Human genes 0.000 claims abstract description 8
- 239000004365 Protease Substances 0.000 claims abstract description 8
- 230000009471 action Effects 0.000 claims abstract description 5
- 239000003102 growth factor Substances 0.000 claims description 41
- 102000004190 Enzymes Human genes 0.000 claims description 22
- 108090000790 Enzymes Proteins 0.000 claims description 22
- 239000000523 sample Substances 0.000 claims description 19
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 12
- 102000004127 Cytokines Human genes 0.000 claims description 11
- 108090000695 Cytokines Proteins 0.000 claims description 11
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 10
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 10
- 108040007629 peroxidase activity proteins Proteins 0.000 claims description 8
- 239000003112 inhibitor Substances 0.000 claims description 7
- 229960002685 biotin Drugs 0.000 claims description 6
- 235000020958 biotin Nutrition 0.000 claims description 6
- 239000011616 biotin Substances 0.000 claims description 6
- 102000019034 Chemokines Human genes 0.000 claims description 5
- 108010012236 Chemokines Proteins 0.000 claims description 5
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 4
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 4
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims description 3
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 claims description 3
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims description 3
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims description 3
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 3
- 102000013462 Interleukin-12 Human genes 0.000 claims description 3
- 108010065805 Interleukin-12 Proteins 0.000 claims description 3
- 108010002350 Interleukin-2 Proteins 0.000 claims description 3
- 108090000978 Interleukin-4 Proteins 0.000 claims description 3
- 108010002586 Interleukin-7 Proteins 0.000 claims description 3
- 108090001007 Interleukin-8 Proteins 0.000 claims description 3
- 102000004890 Interleukin-8 Human genes 0.000 claims description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000003149 assay kit Methods 0.000 claims description 2
- 102100021866 Hepatocyte growth factor Human genes 0.000 claims 2
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 claims 2
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims 2
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 claims 2
- 102000006992 Interferon-alpha Human genes 0.000 claims 2
- 108010047761 Interferon-alpha Proteins 0.000 claims 2
- 102000000588 Interleukin-2 Human genes 0.000 claims 2
- 102000004388 Interleukin-4 Human genes 0.000 claims 2
- 102000000704 Interleukin-7 Human genes 0.000 claims 2
- -1 TGFβl Proteins 0.000 claims 2
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims 2
- 102000003992 Peroxidases Human genes 0.000 claims 1
- 229940088598 enzyme Drugs 0.000 description 20
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 16
- 239000002953 phosphate buffered saline Substances 0.000 description 16
- 108090001008 Avidin Proteins 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 229920002971 Heparan sulfate Polymers 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 230000002942 anti-growth Effects 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 102000013415 peroxidase activity proteins Human genes 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 6
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 6
- 239000012491 analyte Substances 0.000 description 6
- 210000002744 extracellular matrix Anatomy 0.000 description 6
- 108010003272 Hyaluronate lyase Proteins 0.000 description 5
- 102000009066 Hyaluronoglucosaminidase Human genes 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 229960002773 hyaluronidase Drugs 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 108010023736 Chondroitinases and Chondroitin Lyases Proteins 0.000 description 4
- 102000011413 Chondroitinases and Chondroitin Lyases Human genes 0.000 description 4
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 4
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 4
- 230000033115 angiogenesis Effects 0.000 description 4
- 210000002469 basement membrane Anatomy 0.000 description 4
- 210000001772 blood platelet Anatomy 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 229920002683 Glycosaminoglycan Polymers 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 108090000190 Thrombin Proteins 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 108010007093 dispase Proteins 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000007873 sieving Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 2
- 108010088842 Fibrinolysin Proteins 0.000 description 2
- 102000005348 Neuraminidase Human genes 0.000 description 2
- 108010006232 Neuraminidase Proteins 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 210000000585 glomerular basement membrane Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229940012957 plasmin Drugs 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000163 radioactive labelling Methods 0.000 description 2
- 108010038196 saccharide-binding proteins Proteins 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 229960001322 trypsin Drugs 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- BRLRJZRHRJEWJY-VCOUNFBDSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-[3-[3-(4-azido-2-nitroanilino)propyl-methylamino]propyl]pentanamide Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)NCCCN(C)CCCNC1=CC=C(N=[N+]=[N-])C=C1[N+]([O-])=O BRLRJZRHRJEWJY-VCOUNFBDSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010022901 Heparin Lyase Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- 206010027525 Microalbuminuria Diseases 0.000 description 1
- 241001111421 Pannus Species 0.000 description 1
- 101710132772 Peroxidase 1 Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 108010083213 heparitinsulfate lyase Proteins 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 229940127215 low-molecular weight heparin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 210000005059 placental tissue Anatomy 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, e.g. Konjac gum, Locust bean gum, Guar gum
- G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
Definitions
- the present invention relates to an assay for heparanase activity
- Endoglycosidases are capable of cleaving polymers comprised of glycosaminoglycan units (so called "GAG polymers"). Enzymes that cleave a GAG polymer internally are known as endoglycosidases and include heparanase which cleaves heparan sulphate GAG, hyaluronidase which cleaves hyaluronic acid GAG and chondroitinase which cleaves chondroitin sulphate GAG.
- Heparanase has been described in T&B lymphocytes, monocytes, neutrophils, platelets, endothelial cells and in liver and placental tissue. This endoglycosidase activity which degrades heparan sulphate GAG has been variously called heparanase, heparinase, heparitinase and heparan sulphate lyase and almost certainly represents a family of enzymes with different specificities for the internal cleavage site in the GAG polymer.
- Heparan sulphate glycosaminoglycans of which heparin, the anticoagulant is an example, are highly N- and O-sulphated carbohydrate polymers of glucuronic (sometimes iduronic) acid and glucosamine (sometimes N-acetylated).
- the high anionic charge is not randomly distributed throughout the polymer but is thought to form clusters of charged residues imparting specific functional binding properties to the sequence. This is demonstrated by the most important anti-coagulant properties of the pentasaccharide sequence in heparin and its interaction with anti-thrombin III..
- HSGAG is present in the extracellular matrix, in basement membranes and on cell surfaces. HSGAG is known to play an important role in linking the component structural proteins of the basement membrane, controlling the permeability properties of the membrane (best illustrated in the glomerular basement membrane) and controlling the bio-availability of cytokines and growth factors. Heparanases are known to play important roles in areas of discovery biology
- cancer metastasis the most metastatic cells display the highest levels of heparanase enzyme which may enable cancer cells to degrade HSGAG in ECM and basement membranes to facilitate tissue invasion. Cancer cells secreting heparanase may support angiogenesis, tumour vascularisation and therefore tumour growth. This is a prime area for developing novel antagonists to heparanase as part of a therapeutic strategy to supress and inhibit metastasis.
- angiogenesis in the joint may support the chronic inflammatory pathology.
- Agents inhibiting heparanase in the joint may reduce angiogenesis and therefore suppress the formation of the inflammatory pannus of tissue which causes degradation of cartilage and erosion of bone.
- HSGAG expression within the glomerular basement membrane controls the passage of anionic charged proteins e.g. albumin.
- anionic charged proteins e.g. albumin.
- HSGAG expression within the glomerular basement membrane controls the passage of anionic charged proteins e.g. albumin.
- albumin anionic charged proteins
- In vitro metabolic radiolabelling of cell cultures with 35 SO 4 or 3 H incorporated into HSGAG is commonly used for detecting heparanase.
- the radiolabelled GAG may be used following isolation and purification by coupling to a solid phase support.
- radiolabelled ECM laid down on culture dishes with the cell layer removed may be used as substrate.
- 3 H or 125 I labelling of purified HSGAG or heparin is performed and the labelled substrate coupled to a solid phase. Heparanase activity is detected by loss of radiolabel and or reduction in molecular size of labelled species.
- the radiolabelling procedures are hazardous and require special disposal procedures. Large variations in specific activity of substrate occur between batches.
- the batches of 3:, SO 4 substrate have a short lifetime of 2 to 3 months.
- HS Substrate showing sensitivity to other enzymes
- Assays claiming to measure heparanase that use heparan sulphate proteoglycan as the substrate and detect apparent enzyme activity by identifying release of labelled HSGAG or a reduction in the size profile of HSGAG (using isotope or other label) by molecular sieving are not specific for heparanase.
- a wide range of proteases present in the sample could act on the proteoglycan component to solubilise significant quantities of HS chains and cause reduction in size by further removal of attached protein.
- Other enzymes e.g. hyaluronidase may cleave the substrate. Few current assays have demonstrated insensitivity to this range of enzymes.
- a method of assaying a sample to determine heparanase activity thereof comprising
- the invention provides, for the use in an assay as defined above, a solid phase support (equivalent to the aforementioned first support) having immobilised thereon an HSGAG polymer substrate for heparanase, said substrate having bonded thereto a first binding moiety and having further bonded thereto a paracrine cell regulator capable of binding to HSGAG, said first moiety or said paracrine cell regulator being capable of binding to a second moiety.
- the invention provides the combination of first solid phase support as defined in the previous paragraph and second solid phase support having provided thereon a second moiety capable of binding to either the first moiety or the paracrine cell regulator to form a complex therewith.
- the invention provides an assay kit comprising the combination of the previous paragraph and signal developing agents to generate a signal representative of the result of the assay.
- the paracrine cell regulator may, for example, be a growth factor, cytokine or chemokine.
- the assay of the invention allows rapid quantitation of heparanase activity in a sample having, or potentially containing, such activity.
- paracrine cell regulator being an HSGAG binding growth factor but it is to be understood that the invention is equally applicable to other paracrine cell regulators.
- Step (i) of the assay uses a first solid phase support on which is immobilised an HSGAG polymer substrate which is cleavable by the heparanase present (or potentially present) in the sample. Bonded to this polymer substrate are
- the HSGAG substrate bonded to the support is insensitive to the action of proteases at concentrations normally found in clinical samples (otherwise the assay would give a false positive result). This may be achieved by ensuring that the HSGAG substrate is bonded to the first solid phase support otherwise than via any residual small peptide chain in the substrate derived from the proteoglycan from which the HSGAG substrate has been purified.
- the procedure of immobilising the HSGAG substrate on the support may involve oxidation of the sugar residue of the substrate (e.g. using periodate as described in the experimental protocol described infra).
- step (i) results in cleavage of HSGAG polymer substrate in an amount which is dependent on the degree of herparanase activity in the sample and its ability to cleave the HSGAG polymer substrate in the presence of the growth factor bonded thereto.
- HSGAG-growth factor has been removed from the solid phase in step (i) can be obtained after step (ii) by incubating the washed heparanase treated solid phase with (strept)avidin-conjugated enzyme or anti-growth factor conjugated enzyme and comparing the signal with that obtained from a control solid phase. Heparanase activity significantly reduces the signal obtained.
- step (ii) the analyte phase is treated with a second solid phase support system incorporating a second moiety capable either of forming a complex with the first binding moiety or capable or forming a complex with the growth factor.
- a second solid phase support system incorporating a second moiety capable either of forming a complex with the first binding moiety or capable or forming a complex with the growth factor.
- a measurable signal is generated from the cleaved fragments immobilised on the second solid phase support.
- the signal may be dependent on the growth factor component of the complex (where the complex is captured by the first binding moiety and detected with anti-growth factor antibody) and enzyme coupled anti-species antibody.
- the signal may be generated by an enzyme coupled to a third moiety capable of binding to the first moiety.
- the signal may for example, be a colorimetric signal and be measured by a spectrophotometer.
- the signal may be a fluorescent signal which facilities automation of the assay with high throughput.
- step (iv) the signal generated in step (iii) is measured.
- This measurement is effected with the second solid phase support system separated from the first such system (i.e. that employed in step (i)) so that the signal is measured otherwise than in the environment of said first such system.
- the measured signal is representative of the specific heparanase activity in the original sample. More particularly, the measured signal directly reflects the biological action in generating complexes of growth factor-HSGAG that would be produced in physiological and pathological states.
- a critical control point in these pathologies is the bioavailibility of important cytokine, chemokine and growth factors.
- ECM extracellular matrix
- Heparanase enzymes provide critical control of this reservoir by releasing these biologically specific growth factors from ECM that can bind their target receptors and initiate signalling.
- Cytokines that bind HSGAG include IL-l ⁇ and IL-l ⁇ , IL-2, IL-4, IL-7, IL-8, IL-12, TNF ⁇ , IFN ⁇ .
- Chemokines that bind HSGAG include IP-10, MCP-1.
- Growth factors that bind HSGAG include VEGF, FGF-1, FGF-2, TGF ⁇ l, PDGF, HGF. The term growth factor will be used to denote any of these mediators.
- the invention will measure heparanase activity using any of these heparan sulphate binding GFs
- the heparanase-released growth factor in the form of a complex of variable length of HSGAG sequence bound to growth factor may be significantly more active biologically than the native growth factor.
- HSGAG The binding sites in HSGAG that interact with these growth factors are poorly described at present and it may be that each growth factor has a unique binding site. Alternatively, some growth factors may share a certain binding sequence in HSGAG.
- Heparanases from different cell sources may be differentiated from each other by their ability to solubilise particular growth factors or combinations of growth factors from HSGAG. This will happen where the binding of growth factor to the HSGAG substrate protects or sterically occludes a potential enzyme cleavage site.
- a panel of growth factors bound to HSGAG it may be possible to attribute a particular pattern of GF solubilisation to a heparanase from platelets compared to synovial fluid or tumour. This may be of importance for instance in differentiating the action of a tumour heparanase from platelet derived heparanase.
- a specific inhibitor of VEGF solubilisation may reduce and suppress tumour angiogenesis and metastasis without inhibiting the immune functions of a platelet heparanase in solubilising IFN ⁇ to protect from infection during wound healing.
- the assay is unaffected by the presence of proteases, hyaluronidase and chondroitinases.
- the assay is sensitive only requiring incubation times at step (i) of 30-60 minutes.
- the method of the invention may be used for determining heparanase activity in a biological sample, e.g. for the purposes of diagnosing or characterising a particular medical condition. It is however envisaged that an important application of the invention will be in the screening of potential inhibitors or enhancers of heparanase activity.
- the assay may be conducted with an analyte containing an heparanase and a putative inhibitor therefore to determine the effect (or otherwise) of that inhibitor.
- the assay of the invention is particularly useful for determining heparanase activity, e.g. for the purpose of evaluating potential inhibitors thereof.
- the GAG polymer substrate immobilised on the support is preferably heparan sulphate glycosaminoglycan.
- the first solid phase support system (i.e. the system in which the HSGAG polymer substrate is immobilised) is preferably a microtitre well.
- the assay may be conducted using a tray of microtitre wells or larger arrays having immobilised HSGAG polymer substrate.
- the assay of the invention may be effected using robotic technology to screen compounds for anti-heparanase activity.
- the second solid phase support system may be a microtitre plate lid with a coated probe extending into each assay well as the second support system, for example, NUNC® TSP screening system or FALCON® FAST system.
- step (i) and step (ii) of the assay take place during the same incubation time.
- the second solid phase may be another coated microtitre well and step (i) and step (ii) occur sequentially and require physical transfer of the contents of the first well to the second well.
- the first moiety may be biotin and the second moiety strept(avidin).
- the signal may be generated by means of an anti-growth factor antibody and enzyme coupled anti-species antibody.
- the second moiety may be anti-growth factor antibody.
- the first moiety may be biotin and the signal generated by an enzyme coupled to (strept)advin (as the aforementioned third moiety).
- the method of the invention may be effected using the following protocol.
- the GAG polymer substrate may be tagged with biotin using simple photobiotylation chemistry.
- a mixture of photobiotin (lmg/ml) and HSGAG (lOmg/ml) in phosphate buffered saline (PBS) at a ratio of 2:1 (vol/vol) is exposed to UV light emitted from a Mercury arc HBO50 W lamp used as a microscope UV source for 21 minutes at a distance of 10 cm.
- the biotinylated HSGAG is dialysed against PBS for 18 hours at 4°C and stored at -20°C.
- the immobilisation of the GAG polymer substrate on the solid phase support is carried out after the tagging with the first complex forming moiety and may be effected by oxidising the substrate with periodate and incubation with carbohydrate binding multiwell plates (for example, COSTAR® or NUNC plates may be used) to yield a surface to which the substrate is covalently and stably bonded.
- carbohydrate binding multiwell plates for example, COSTAR® or NUNC plates may be used
- the GAG polymer substrate may be treated with a GAG binding growth factor (e.g. VEGF, TGF ⁇ l, MCP-1, IFN- ⁇ , see list in claim 8).
- a GAG binding growth factor e.g. VEGF, TGF ⁇ l, MCP-1, IFN- ⁇ , see list in claim 8.
- lOO ⁇ l of GF at l-5 ⁇ g/ml in PBS is added to each well and incubated for 18 hours at 4°C. Following washing in PBS, the plate is ready for use.
- the second solid phase support may be prepared by coating the support material with the second complex forming moiety (e.g. (strep)avidin blocked with BSA).
- the microwell lid probes or wells, where the second solid phase is another well, are coated with (strept)avidin at l-5 ⁇ g/ml in PBS for 18 hours and following washing in PBS they are blocked with BSA as above.
- the analyte having (or potentially having) heparanase activity is incubated in the presence of the first solid phase support system.
- the analyte is diluted in enzyme assay buffer which is sodium acetate (0.1M, pH 5.5 containing Ca 2+ (5mM), Cu 2+ (ImM) and Fe 3+ (ImM).
- Each assay includes as controls, wells without biotinylated HSGAG coating and wells which do not receive the test sample.
- the heparanase assay is allowed to proceed for 1 hour normally (but may range from 30minutes to 4 hours) on a plate shaker at 37°C.
- steps (i) and (ii) occur simultaneously, where the second solid phase is another coated well, the supernatant from the first well is transferred to the second well and incubated for 2 to 24 hours.
- any biotinylated HSGAG-GF substrate cleaved from the first solid phase support during incubation becomes immobilised on the second support which may now be separated from the analyte.
- a signal is then developed.
- the second solid phase used strep(avidin) to capture the complex through its biotin moiety this may be achieved by incubating the second solid phase support with anti-growth factor antibody followed by enzyme- conjugated anti-species IgG.
- the second solid phase used anti-growth factor antibody to capture the complex signal may be developed by incubating with enzyme-conjugated strep(avidin).
- Confirmation that the substrate bound to the first solid phase has been cleaved can be obtained by incubation with either enzyme conjugated strep(avidin) or enzyme conjugated antibody.
- the preferred enzyme conjugated to these detection reagents is peroxidase and therefore the amount of peroxidase activity associated with the well probe may be revealed using a standard TMB substrate colour change and spectrophotometry.
- This Reference Example demonstrates the specificity of biotinylated HSGAG for heparanase.
- Biotinylated HSGAG was prepared using the procedure described in the above protocol and immobilised on microtitre wells as the solid phase support, again using the procedure of the protocol
- the % release of HSGAG was determined by the following procedure. 1 OO ⁇ l of avidin peroxidase at 1 : 1000 dilution in PBS was added to the plate for 60 mins at 37 °C. After washing three times in PBS Tween, lOO ⁇ l of TMB substrate (lOOug/ml) was added and the colour development was assayed in end point mode at 450nm after stopping the reaction with lOOul of 0.1 M HC1.
- Fig 1 clearly demonstrates the specifity of the biotinylated HSGAG for Heparanase.
- This Reference Example demonstrates that support-bound biotinylated HSGAG is cleaved from the solid phase by heparanase treatment.
- a dilution series of spleen extract of heparanase was prepared, added to separate samples of the support-bound HSGAG substrate and incubated for 60 minutes. The support was then washed followed by addition of avidin peroxidase 1 : 1000 for 30-60 minutes at 37 ° C. Peroxidase substrate TMB lOOug/ml was added and colour change measured by spectrophotometry.
- Biotinylated HSGAG prepared as in the above described protocol was immobilised on a solid support using the procedure of the above described protocol.
- Recombinant growth factor/cytokine (63ng/ml in PBS) was incubated in the wells overnight to allow binding to the HSGAG and form a solid phase bound complex. Unbound GF/cytokine was removed by washing three times with PBS. A standard dilution 1 :20 of spleen heparanase enzyme was added to the wells for one hour and the amount of GF/cytokine remaining was detected by use of a specific anti-GF/cytokine antibody. This antibody was detected by an anti-species peroxidase coupled reagent followed by substrate development.
- Biotinylated HSGAG prepared as in the above described protocol was immobilised on a solid support, again using the procedure of the protocol.
- Recombinant VEGF (63 ng/ml in PBS) was incubated in the wells overnight to allow binding to the HSGAG and form a solid phase bound complex of the HSGAG and VEGF.
- Unbound VEGF was removed by washing three times with PBS.
- Heparanase enzyme from spleen at 1 :10 dilution was added to the wells for one hour. Subsequently the well contents were transferred to another ELISA plate precoated with monoclonal anti-VEGF antibody (5 ⁇ g/ml for 16 hours) and incubated for 4 hours. During incubation, heperanase cleaved soluble complexes containing biotinylated HSGAG bound to VEGF (which complexes are derived from the first plate) were bound to the anti-VEGF coated plate. After washing, the presence of biotinylated HSGAG bound to the anti-VEGF well was detected with avidin peroxidase followed by addition of peroxidase substrate.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002376534A CA2376534A1 (en) | 1999-06-10 | 2000-06-12 | Heparanase assay |
EP00938900A EP1190250A2 (en) | 1999-06-10 | 2000-06-12 | Heparanase assay |
JP2001503682A JP2003502054A (en) | 1999-06-10 | 2000-06-12 | Heparanase assay |
AU54125/00A AU5412500A (en) | 1999-06-10 | 2000-06-12 | Heparanase assay |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9913415.7 | 1999-06-10 | ||
GBGB9913415.7A GB9913415D0 (en) | 1999-06-10 | 1999-06-10 | Heparanase assay |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000077241A2 true WO2000077241A2 (en) | 2000-12-21 |
WO2000077241A3 WO2000077241A3 (en) | 2001-03-22 |
Family
ID=10855020
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2000/002117 WO2000077241A2 (en) | 1999-06-10 | 2000-06-12 | Heparanase assay |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1190250A2 (en) |
JP (1) | JP2003502054A (en) |
AU (1) | AU5412500A (en) |
CA (1) | CA2376534A1 (en) |
GB (1) | GB9913415D0 (en) |
HU (1) | HUP0202362A2 (en) |
WO (1) | WO2000077241A2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2833614A1 (en) * | 2001-12-18 | 2003-06-20 | Hoffmann La Roche | Test for inhibitors of heparanase, useful for treatment of e.g. cancer and inflammatory disease, using immobilized, labeled heparanase substrate |
US6656699B2 (en) | 2000-09-15 | 2003-12-02 | Reddy Us Therapeutics, Inc. | Methods and compositions for glycosidase assays |
FR2843126A1 (en) * | 2002-08-01 | 2004-02-06 | Cis Bio Int | "METHOD FOR DETERMINING ENZYMATIC ENDOGLYCOSIDASE ACTIVITY" |
WO2012025069A1 (en) * | 2010-08-27 | 2012-03-01 | Christian-Albrechts-Universität Zu Kiel | Method for determining the enzyme activity of heparanase |
ES2564426A1 (en) * | 2014-09-19 | 2016-03-22 | Universidad De Oviedo | Ocular pathology marker (Machine-translation by Google Translate, not legally binding) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101983051B (en) | 2008-03-31 | 2013-04-24 | 株式会社资生堂 | Preparation for preventing or ameliorating wrinkles, to be taken orally, through injection, or through external application to skin, and cosmetic method |
JP2012505441A (en) | 2009-03-24 | 2012-03-01 | 株式会社日立製作所 | Storage apparatus and data control method thereof |
JP5593323B2 (en) | 2009-09-30 | 2014-09-24 | 株式会社 資生堂 | Heparanase activity inhibitor |
KR101736519B1 (en) | 2009-09-30 | 2017-05-16 | 가부시키가이샤 시세이도 | Heparanase-activity inhibitor, wrinkle ameliorating agent containing same, and pharmaceutical composition |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5185434A (en) * | 1985-02-13 | 1993-02-09 | Sanofi | Prolonged-action immunotoxins containing a glycopeptide constituent which inactivates ribosomes, modified on its polysaccharide units |
US5332812A (en) * | 1986-03-10 | 1994-07-26 | Board Of Regents, The University Of Texas System | Solid-phase substrate containing modified heparin |
WO1994020512A2 (en) * | 1993-03-01 | 1994-09-15 | Glycan Pharmaceuticals, Inc. | Analogs for specific oligosaccharide-protein interactions and uses therefor |
WO2000003036A1 (en) * | 1998-07-10 | 2000-01-20 | Insight Strategy & Marketing Ltd. | Method of screening for potential anti-metastatic and anti-inflammatory agents using mammalian heparanase as a probe |
-
1999
- 1999-06-10 GB GBGB9913415.7A patent/GB9913415D0/en not_active Ceased
-
2000
- 2000-06-12 EP EP00938900A patent/EP1190250A2/en not_active Withdrawn
- 2000-06-12 WO PCT/GB2000/002117 patent/WO2000077241A2/en not_active Application Discontinuation
- 2000-06-12 JP JP2001503682A patent/JP2003502054A/en active Pending
- 2000-06-12 HU HU0202362A patent/HUP0202362A2/en unknown
- 2000-06-12 CA CA002376534A patent/CA2376534A1/en not_active Abandoned
- 2000-06-12 AU AU54125/00A patent/AU5412500A/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5185434A (en) * | 1985-02-13 | 1993-02-09 | Sanofi | Prolonged-action immunotoxins containing a glycopeptide constituent which inactivates ribosomes, modified on its polysaccharide units |
US5332812A (en) * | 1986-03-10 | 1994-07-26 | Board Of Regents, The University Of Texas System | Solid-phase substrate containing modified heparin |
WO1994020512A2 (en) * | 1993-03-01 | 1994-09-15 | Glycan Pharmaceuticals, Inc. | Analogs for specific oligosaccharide-protein interactions and uses therefor |
US5795860A (en) * | 1993-03-01 | 1998-08-18 | Repligen Corporation | Analogs for specific oligosaccharide-protein interactions and uses therefor |
WO2000003036A1 (en) * | 1998-07-10 | 2000-01-20 | Insight Strategy & Marketing Ltd. | Method of screening for potential anti-metastatic and anti-inflammatory agents using mammalian heparanase as a probe |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6656699B2 (en) | 2000-09-15 | 2003-12-02 | Reddy Us Therapeutics, Inc. | Methods and compositions for glycosidase assays |
FR2833614A1 (en) * | 2001-12-18 | 2003-06-20 | Hoffmann La Roche | Test for inhibitors of heparanase, useful for treatment of e.g. cancer and inflammatory disease, using immobilized, labeled heparanase substrate |
FR2840322A1 (en) * | 2001-12-18 | 2003-12-05 | Hoffmann La Roche | METHODS FOR TESTING THE POTENTIAL OF AN AGENT FOR INHIBITING THE CATALYTIC ACTIVITY OF HEPARANASE. |
US7081351B2 (en) | 2001-12-18 | 2006-07-25 | Hoffmann-La Roche Inc. | Method for screening an agent for ability to inhibit heparanase activity |
US7625999B2 (en) | 2001-12-18 | 2009-12-01 | Hoffmann-La Roche Inc. | Method for testing the ability of an agent to inhibit fibroblast growth factor binding with labeled heparan sulfate |
FR2843126A1 (en) * | 2002-08-01 | 2004-02-06 | Cis Bio Int | "METHOD FOR DETERMINING ENZYMATIC ENDOGLYCOSIDASE ACTIVITY" |
WO2004013348A3 (en) * | 2002-08-01 | 2004-04-08 | Cis Bio Int | Method for determining endoglycosidase enzyme activity |
US7838211B2 (en) | 2002-08-01 | 2010-11-23 | Cis Bio International | Method for determining endoglycosidase enzyme activity |
WO2012025069A1 (en) * | 2010-08-27 | 2012-03-01 | Christian-Albrechts-Universität Zu Kiel | Method for determining the enzyme activity of heparanase |
ES2564426A1 (en) * | 2014-09-19 | 2016-03-22 | Universidad De Oviedo | Ocular pathology marker (Machine-translation by Google Translate, not legally binding) |
WO2016042196A1 (en) | 2014-09-19 | 2016-03-24 | Universidad De Oviedo | Marker of ocular pathologies |
Also Published As
Publication number | Publication date |
---|---|
EP1190250A2 (en) | 2002-03-27 |
JP2003502054A (en) | 2003-01-21 |
CA2376534A1 (en) | 2000-12-21 |
WO2000077241A3 (en) | 2001-03-22 |
HUP0202362A2 (en) | 2002-10-28 |
AU5412500A (en) | 2001-01-02 |
GB9913415D0 (en) | 1999-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0394398B1 (en) | Nanoparticle with bound enzyme and bound ligand useful in analysis | |
EP2643475A1 (en) | Analysis of direct factor xa inhibitors | |
EP1190250A2 (en) | Heparanase assay | |
US20070184504A1 (en) | Assay for anti-INGAP antibodies | |
JP3698563B2 (en) | Method and kit for measuring glycosaminoglycan | |
FI100276B (en) | Method for non-competitive determination of analytes | |
US20210132091A1 (en) | Collagen iv binding assay for the detection of collagen vii | |
US5183735A (en) | Method and diagnostic test kit for detection of anti-dsDNA antibodies | |
JP3282129B2 (en) | Solid phase non-separable enzyme analysis | |
US20200264177A1 (en) | Compositions and methods for diagnosing and assessing rheumatoid arthritis | |
US10890586B2 (en) | Methods and kits for assaying endoglycosidase activity | |
EP0658251A1 (en) | Water soluble polymers for use in immunoassays and dna hybridization assays | |
JP2004529606A (en) | Methods and compositions for glycosidase assays | |
JP2000111553A (en) | Measuring method for normal aggrecan and its application | |
Burlingame et al. | Enzyme-linked immunosorbent assays for diagnostically important antinuclear antibodies | |
JP2000009733A (en) | Measuring method and measurement kit for sugar chain coupling physiological active material | |
US20090269790A1 (en) | Method and Apparatus for Determining Hemocompatibility | |
JPH08509064A (en) | Immobilization of chemically crosslinked proteins on a solid support | |
JP2005328752A (en) | Method for assaying activity of glycosaminoglycan splitting enzyme | |
EP1840572A1 (en) | A system for the enhancement of the detection of antibodies directed against red cell antigens | |
CA2021048A1 (en) | Method of determining antigens and/or antibodies in human body liquids | |
JPH08334513A (en) | Recuperation judgement of c-type chronic hepatitis after treatment with interferon | |
JP2002340902A (en) | Method for measuring microorganisms or microbial components and measuring kit using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 503682 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000938900 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 54125/00 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2376534 Country of ref document: CA Ref country code: CA Ref document number: 2376534 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 2000938900 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10018260 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000938900 Country of ref document: EP |